The impact of antipsychotics as a risk factor for thromboembolism

[1]  V. Calsolaro,et al.  The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease , 2019, Front. Pharmacol..

[2]  S. Kasper,et al.  Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[3]  Masaru Mimura,et al.  Incidence of deep vein thrombosis in catatonic patients: A chart review , 2016, Psychiatry Research.

[4]  S. Ayis,et al.  Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders , 2016, European Psychiatry.

[5]  S. Marchini,et al.  Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. , 2016, Thrombosis research.

[6]  A. John,et al.  A case report of clozapine continuation after pulmonary embolism in the context of other risk factors for thromboembolism , 2016, The Australian and New Zealand journal of psychiatry.

[7]  I. Jalenques,et al.  [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients]. , 2016, L'Encephale.

[8]  B. Schneider,et al.  Elevated Rest Heart Rate in Psychiatric Patients and Different Effects of Psychotropic Medication , 2015, Pharmacopsychiatry.

[9]  S. Janković,et al.  Long-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome , 2015 .

[10]  M. Uchiyama,et al.  One-Year Follow-Up of Serum Prolactin Level in Schizophrenia Patients Treated with Blonanserin: A Case Series , 2015, Psychiatry investigation.

[11]  Wai Keung Christopher Lai,et al.  Homocysteine-Induced Endothelial Dysfunction , 2015, Annals of Nutrition and Metabolism.

[12]  J. Heit.  Epidemiology of venous thromboembolism , 2015, Nature Reviews Cardiology.

[13]  P. Ferri,et al.  Homocysteine levels in schizophrenia patients newly admitted to an acute psychiatric ward , 2015, Acta Neuropsychiatrica.

[14]  Kathleen McCurdy,et al.  Introduction of a Venous Thromboembolism Prophylaxis Protocol for Older Adult Psychiatric Patients. , 2015, BMJ quality improvement reports.

[15]  Norio Sugawara,et al.  Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers , 2015, Neuropsychiatric disease and treatment.

[16]  C. Voulgari,et al.  Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis , 2015, Case reports in medicine.

[17]  L. Guan,et al.  Pulmonary Thromboembolism Associated with Olanzapine Treatment , 2015, Chinese medical journal.

[18]  Bahadır Külah,et al.  Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins , 2015, Pakistan journal of medical sciences.

[19]  A. Cohen,et al.  Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved? , 2014, British journal of haematology.

[20]  M. Mimura,et al.  Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. , 2014, General hospital psychiatry.

[21]  David N. Kennedy,et al.  Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia , 2014, Schizophrenia Research.

[22]  O. Andreassen,et al.  Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions , 2014, Front. Psychiatry.

[23]  M. Serinken,et al.  Pulmonary thromboembolism due to paliperidone: report of 2 cases. , 2014, The American journal of emergency medicine.

[24]  A. Cipriani,et al.  Antipsychotic Drug Exposure and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational Studies , 2014, Drug Safety.

[25]  E. Garbe,et al.  Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients With Dementia , 2013, Journal of clinical psychopharmacology.

[26]  Carmen Gonzalez,et al.  Prolactin and blood-brain barrier permeability. , 2013, Current neurovascular research.

[27]  V. Stefanović,et al.  Fatal pulmonary thromboembolism after prolonged physical immobilization in hospitalized psychiatric patients. , 2013, Vojnosanitetski pregled.

[28]  M. Jakovljevič,et al.  Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia , 2013, Nordic journal of psychiatry.

[29]  J. Geddes,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[30]  S. Praharaj,et al.  Clozapine-induced recurrent pulmonary thromboembolism. , 2013, The Journal of neuropsychiatry and clinical neurosciences.

[31]  C. Correll,et al.  Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? , 2013, The Journal of clinical psychiatry.

[32]  P. Manu,et al.  Thrombotic complications of treatment with antipsychotic drugs. , 2013, Minerva medica.

[33]  Cuntai Zhang,et al.  Fatal multisystem venous thrombosis associated with clozapine. , 2013, Journal of clinical psychopharmacology.

[34]  S. Patted,et al.  Pulmonary thromboembolism associated with clozapine. , 2013, The Journal of neuropsychiatry and clinical neurosciences.

[35]  M. Hamza,et al.  [Specific treatments of the psychiatric community and thrombogenesis]. , 2013, L'Encephale.

[36]  P. Gourzis,et al.  Pulmonary Embolism Related to Amisulpride Treatment: A Case Report , 2013, Case reports in psychiatry.

[37]  B. Mercier,et al.  Incidence of venous thromboembolism in psychiatric units. , 2012, Thrombosis research.

[38]  O. Dekkers,et al.  Levels of prolactin in relation to coagulation factors and risk of venous thrombosis , 2012, Thrombosis and Haemostasis.

[39]  B. Allenet,et al.  Antipsychotic drugs and risk of pulmonary embolism , 2012, Pharmacoepidemiology and drug safety.

[40]  F. Shao,et al.  Antipsychotics and Venous Thromboembolism Risk: A Meta-Analysis , 2011, Pharmacopsychiatry.

[41]  B. Tzang,et al.  Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia , 2011, Psychiatry Research.

[42]  Michael L. Johnson,et al.  Risk of serious cardiac events in older adults using antipsychotic agents. , 2011, The American journal of geriatric pharmacotherapy.

[43]  M. Valis,et al.  Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study , 2011, BMC psychiatry.

[44]  T. Egberts,et al.  Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients , 2010, Journal of clinical psychopharmacology.

[45]  J. Hippisley-Cox,et al.  Antipsychotic drugs and risk of venous thromboembolism: nested case-control study , 2010, BMJ : British Medical Journal.

[46]  K. Fehsel,et al.  Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients , 2010, International clinical psychopharmacology.

[47]  K. Naeem,et al.  Olanzapine and pulmonary embolism, a rare association: a case report , 2010, Cases journal.

[48]  M. Nikolova,et al.  Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication , 2009, Psychiatry Research.

[49]  O. Spigset,et al.  Risk of venous thromboembolism due to antipsychotic drug therapy , 2009, Expert opinion on drug safety.

[50]  J. Foong,et al.  Cerebral venous sinus thrombosis may be associated with clozapine. , 2009, The Journal of neuropsychiatry and clinical neurosciences.

[51]  M. Rochas,et al.  Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. , 2009, The Journal of clinical psychiatry.

[52]  E. Hodneland,et al.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner , 2009, Journal of chemical biology.

[53]  Jianfang Chen,et al.  Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. , 2009, Journal of psychiatric research.

[54]  C. Mcauley,et al.  Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies. , 2009, Irish medical journal.

[55]  L. Hosák,et al.  Four cases of venous thromboembolism associated with olanzapine , 2009, Psychiatry and clinical neurosciences.

[56]  I. Nazareth,et al.  Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis , 2008, BMC psychiatry.

[57]  E. Constant,et al.  Pulmonary thromboembolism associated with olanzapine and risperidone. , 2008, The Journal of emergency medicine.

[58]  V. Fernández,et al.  Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives , 2008, Schizophrenia Research.

[59]  R. Morgan,et al.  Massive pulmonary emboli associated with olanzapine. , 2008, Irish medical journal.

[60]  L. Hosák,et al.  Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients , 2008, Psychiatry and clinical neurosciences.

[61]  J. Metzner,et al.  Resource document on the use of restraint and seclusion in correctional mental health care. , 2007, The journal of the American Academy of Psychiatry and the Law.

[62]  T. Lindahl,et al.  IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION , 2007, Clinical and experimental pharmacology & physiology.

[63]  J. Suvisaari,et al.  Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. , 2007, The Journal of clinical psychiatry.

[64]  M. Cushman.  Epidemiology and risk factors for venous thrombosis. , 2007, Seminars in hematology.

[65]  W. Daniel,et al.  Increased Prolactin in Acute Coronary Syndromes as Putative Co-activator of ADP-stimulated P-Selectin Expression , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[66]  J. Hietala,et al.  Cigarette smoking in long-term schizophrenia , 2006, European Psychiatry.

[67]  V. Mor,et al.  Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. , 2005, Archives of internal medicine.

[68]  C. Hennekens,et al.  Schizophrenia and increased risks of cardiovascular disease. , 2005, American heart journal.

[69]  S. Sidorowicz.  [The comparison of immobilization with isolation]. , 2005, Psychiatria polska.

[70]  N. Makhoul,et al.  Fatal Venous Thromboembolism Associated with Antipsychotic Therapy , 2004, The Annals of pharmacotherapy.

[71]  H. Miyaoka,et al.  Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[72]  Kun-Jung Chung,et al.  Massive pulmonary embolism in a young patient on clozapine therapy. , 2004, The Journal of emergency medicine.

[73]  H. Gertz,et al.  Hyperprolactinemia in Patients on Antipsychotic Drugs Causes ADP-Stimulated Platelet Activation That Might Explain the Increased Risk for Venous Thromboembolism: Pilot Study , 2003, Journal of clinical psychopharmacology.

[74]  H. Büller,et al.  Clozapine and venous thromboembolism: further evidence. , 2003, The Journal of clinical psychiatry.

[75]  T. Dinan,et al.  Elevated expression of integrin αIIb βIIIa in drug-naïve, first-episode schizophrenic patients , 2002, Biological Psychiatry.

[76]  R. Belmaker,et al.  Elevated homocysteine levels in young male patients with schizophrenia. , 2002, The American journal of psychiatry.

[77]  G. Zornberg,et al.  Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study , 2000, The Lancet.

[78]  O. Spigset,et al.  Association of venous thromboembolism and clozapine , 2000, The Lancet.

[79]  S. Neshige,et al.  [Cerebral venous sinus thrombosis associated with hyperhomocysteinemia due to combined deficiencies of folate and vitamin B12]. , 2016, Rinsho shinkeigaku = Clinical neurology.

[80]  M. Bernardo,et al.  Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: The CRESSOB study. , 2016, Actas espanolas de psiquiatria.

[81]  M. Mimura,et al.  Incidence of deep vein thrombosis in restrained psychiatric patients. , 2014, Psychosomatics.

[82]  N. Khammassi,et al.  [Management of venous thromboembolism in psychiatric patients]. , 2012, La Tunisie medicale.

[83]  M. Ståhl,et al.  Associations Between Venous Thromboembolism and Antipsychotics , 2008, Drug safety.

[84]  H. Slor,et al.  Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia , 2005, Journal of Clinical Immunology.

[85]  J. Lieberman.  Dopamine Partial Agonists , 2004, CNS drugs.

[86]  thromboembolism: A population-based , 2022 .